Navigation Links
Neurobiological Technologies' CEO to Retire on December 31, 2008
Date:7/7/2008

EMERYVILLE, Calif., July 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. The Company expects Mr. Freiman to continue to serve on the Board. Mr. Freiman is the former chief executive officer of Syntex Corporation of Palo Alto, California.

Mr. Freiman is retiring after 11 years of service to the company. "Paul's strong leadership has helped grow our company to where we have a Phase 3 program in a highly underserved acute ischemic stroke market and his contributions with XERECEPT(R) and Memantine to our organization will be long- lasting. We thank him for his dedicated service and wish him the best as he moves on to the next chapter in his life," said Abraham E. Cohen, NTI's chairman of the Board of Directors.

Mr. Freiman stated, "Since I stepped into the role of an interim CEO in 1997, I have enjoyed all aspects of my time at NTI. I remain committed to our principal product, Viprinex(TM), which may provide an extraordinary opportunity in the treatment of acute ischemic stroke. I have announced my intent so that the Board of Directors has sufficient time to thoughtfully identify my successor. I will direct our operations with vigor over the next six months and continue to be an active NTI director beyond my retirement."

A committee has been formed by the Board of Directors, headed by NTI director, William A. Fletcher, Chairman of Teva North America, to search for a new CEO and has engaged the services of a retained search firm.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Neurobiological Technologies Sets Date for Third Quarter Financial Results
3. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
5. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Sets Date for Research and Development Day
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
9. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
10. Neurobiological Technologies Sets Date for Second Quarter Financial Results
11. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... CAMBRIDGE, Mass. and ... 4, 2016 SystemOne, a company focused ... platforms for the developing world, and Daktari Diagnostics, ... reality with its portable and ultrasensitive immunoassay-based CarePlatform™, ... development and license agreement to integrate Daktari,s technology ...
(Date:12/2/2016)... Dec. 2, 2016 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced the appointment of ... industry consultant, and private healthcare investor, to its Board ... leader with clinical and strategic experience at the highest ... and CEO. "As one of the world,s leading orthopedic ...
(Date:12/2/2016)... NC (PRWEB) , ... December 01, 2016 , ... ... US Computational Science Symposium (CSS) and the popularity of US Single Day Events ... take place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center ... 3rd, 2016. The event, which is held on the United Nations International Day of ... Disabilities back into the workplace. Suitable Technologies is partnering with NTI to showcase how ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
Breaking Biology News(10 mins):